Q1 2025 SeQuent Scientific Ltd Earnings Call Transcript
Key Points
- Sequent Scientific Ltd (BOM:512529) reported a strong revenue growth of 17.1% year-over-year for Q1 FY25, reaching INR3,902 million.
- The company achieved its highest recorded quarterly EBITDA pre-ESOP in the last three years at INR483 million, translating to an EBITDA pre-ESOP margin of 12.4%.
- The formulation business, which accounts for three-fourths of the company's revenues, showed a robust growth of 21.1% year-over-year.
- Sequent Scientific Ltd (BOM:512529) received EU GMP certification for its manufacturing facility in Turkey, enhancing its export capabilities.
- The company has successfully completed its term loan restructuring, simplifying its borrowing structure and creating additional lines to support future business growth.
- The company faces challenges in the Turkey market due to inflation and currency fluctuations, although the environment is improving.
- Interest costs have increased due to the term loan restructuring process, which may impact short-term financial performance.
- The India formulation business is still in the early stages of expansion and may take time to deliver significant results.
- The company is not currently manufacturing vaccines but is distributing them, which may limit its control over this segment.
- Working capital days have increased to 110-120 days, up from the previous 80-90 days, due to geographical spread and logistical challenges.
Ladies and gentlemen, good day, and welcome to the Sequent Scientific Limited Q1 and FY25 earnings conference call. (Operator Instructions)
Please note that this conference is being recorded. I now hand the conference over to Mr. Abhishek. Thank you, and over to you, sir.
A very good morning, and thank you for joining us today for Sequent Scientific's earnings conference call for the first quarter and full year ended financial year 2024. Today, we will have with us Rajaram, Sequent's Managing Director; and Saurav, CFO, to share the highlights of the business and financials for the quarter.
I hope you've gone through our results release and the quarterly investor presentation, which have been uploaded on our website, as well as stock exchange website. The transcript of this call will be available in a week's time on the company's website. Please note that today's discussion may be forward-looking in nature and must be viewed in relation to the risks pertaining to our business.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
